CyberKnife radiosurgery for selected patients with prostate cancer. Usually 5 outpatient sessions, with no anaesthesia and no hospital stay.
Treat Prostate Cancer
Without Surgery
Short course Non-invasive Outpatient
Reasons to Consider CyberKnife for Prostate Cancer
Your path to recovery deserves the most advanced, least disruptive solution.
CyberKnife may suit men with localised prostate cancer who want a short, non-surgical course of treatment. Whether it suits you depends on your diagnosis.
Protect Your Health While Treating Cancer
CyberKnife targets the tumor – not your body.
Unlike conventional radiation therapy, which typically requires 30–40 sessions over several weeks and exposes healthy tissues to radiation, CyberKnife uses robotic precision to deliver just 5 focused treatments with minimal impact on surrounding organs.
Treatment usually takes 1-2 weeks
The course is usually 5 sessions, given on working days or every other working day.
Ultra-precision and minimal risk of side effects
CyberKnife tracks the prostate during treatment and adjusts the beam with sub-millimetre accuracy. This helps limit the dose to the bladder and rectum. Side effects are possible – most are mild and temporary.
Preserve your quality of life and dignity
There is no surgery, so there are no surgical wounds and no recovery from a catheter. Effects on urinary, bowel and sexual function are possible – your doctor will discuss your individual risk.
Return to your lifestyle seamlessly
Most patients continue their usual daily activities during the treatment course.
Radiation oncologist
Maris Mezeckis
Dr. Mezeckis is the lead radiation oncologist at Radiosurgery Centre Sigulda and has treated patients with CyberKnife since 2015. His focus is prostate cancer and metastatic disease.


Customer Consultant
Daina Svarinska
Daina is your patient coordinator. Send her your medical documents – there is no charge for the initial assessment, which shows whether CyberKnife may be suitable for you. With her background as a nurse, she will guide you through each step.
Cancer treatment results
Oscar (75), Low risk prostate cancer
“I am 75 years old and I have always thought of myself as a healthy person. I have been living healthy since young age, and I still continue working. The only exception in my health condition is that I have to get up several times during the night to go to toilet. Sometimes it causes inconvenience, but apart from that, other functions seem to be alright. Besides, a year ago I scheduled a visit to an urologist.
During the examination the treating doctor detected enlarged prostate and that the level of prostate-specific antigen (PSA) has elevated from 5 to 11.
Doctor told that prostate biopsy is needed to specify the diagnosis. Some tumour cells were found in one of samples and it meant that I have prostate cancer in early stage. He explained to me and my wife the examination results, possible treatment options and potential complications. I was offered a prostate surgery. Unfortunately, due to possible side effects about which I read in stories of other patients, I decided to refuse from the offered treatment.
I waited for another six months and then attended the urologist repeatedly, because the PSA level was still elevated, and therefore the urologist recommended radiotherapy. Conventional radiotherapy lasts for six weeks, but due to my work schedule I could not take such treatment and the very disease, according to doctor, was in the early stage. The urologist informed me about possibility to try a new and progressive radiosurgery system, CyberKnife, which was suitable also for my case, and referred me to a consultation to the Radiosurgery Centre in Sigulda. After consultation in Sigulda I was scheduled for five radiotherapy sessions with the CyberKnife system instead of thirty conventional sessions. I attended the procedures three months ago, just as planned.
Treatment process was a real surprise. Both professionalism and technical competence and careful attitude and attention of the staff was very good. The procedures were scheduled in a time convenient for me, on the second half of the day, taking into consideration the busy work schedule that I had. I could completely adapt it to my routine day at work. And, to be honest, I did not feel any discomfort.
Of course, it is too early to say that the cancer has fully disappeared. Doctors told that it would take some time to see if the process is becoming stable. Besides, neither during the treatment nor now I have any of those severe side effects the urologist referred to. Everything seems to work fine and also the PSA level got slightly lower during the first control one month later. During the treatment and also afterwards I carefully comply with the recommendations given by the doctor from the Radiosurgery Centre; so each of us have done their part of the job.
I can recommend patients with urological problems and prostate cancer diagnosis similar to mine to take a consultation and treatment in Sigulda. Staff working in the Centre is competent and treatment with CyberKnife progressed as described in the consultation. I express gratitude to the medical staff for great care and comfortable, almost cosy atmosphere in the Radiosurgery Centre Sigulda. I am grateful to all of them and my only wish is that people suffering from problems similar to mine could afford coming to Sigulda and be treated with CyberKnife. They won’t be disappointed for making such a decision.”
Doctor’s commentary
Patient was diagnosed with low risk of recurrence and a metastasis-forming tumour, however it progressed through gradual increase of PSA level in the blood. In such cases radical treatment is justified. In a multicentre trial of 309 men treated with five-session CyberKnife SBRT, 5-year disease-free survival in low-risk prostate cancer was 97.3% (Meier et al., Int J Radiat Oncol Biol Phys 2018; trial sponsored by Accuray, the CyberKnife manufacturer). In a single-centre series of 230 low-risk patients, 10-year biochemical disease-free survival was 93.7% and local control was 98.4% (Katz, Cureus 2017). Individual results may differ. Patient had slight side effects after the therapy that disappeared few weeks later, allowing literally the same quality of life as before the therapy.
Gatis (44), doctor, High risk prostate cancer
“In October 2016, within the framework of preventive examination, I was detected an elevated prostate-specific antigen (PSA), standing at 11.3 ng/ml (standard threshold up to 4.0 ng/ml). I had no complaints. Control analyses one week later still showed an increased PSA therefore I made an appointment with an urologist.
The urologist performed transrectal ultrasonoscopy with targeted prostate biopsy in order to specify a diagnosis, finding atypical cells in one out of twelve samples. In November 2016, on the basis of biopsy results, the diagnosis —prostate cancer —was confirmed.
In order to decide on further treatment tactics, the urologist recommended performing MRI examination for the prostate. Magnetic resonance imaging exam confirmed new lesion in the left lobe of prostate without extracapsular growth.
It was followed by a question—what to do? Considering all aspects—my age, PSA index, Gleason score 7 and finding from the MRI scan —the urologist offered radical treatment methods like prostatectomy or surgical removal of the prostate. The physician also informed me about possible complications after the surgery, including complete loss of potency and inconsistency of varied severity. Faced with seriousness of the situation and consequences of the surgical treatment, I started to look for tumour treatment alternatives. If I were 80 years old, I would not give a second thought, but if there are alternatives of treatment nowadays, I want to know them.
In spring 2017, in an internet portal I foundan information about robotic stereotactic radiosurgery treatment possibilities in Sigulda. I found out that robotic stereotactic radiosurgery technology CyberKnife treats tumours of various origin and localisation, including primary prostate tumour.
In order to find out more about possibilities to be treated with this method, I made an appointment with a radiation oncologist. According to recommendations of the radiation oncologist I had positron emission tomography (PET) performed with preparation 68Ga-PSMA, which is currently recognised as the most precise diagnostic method for prostate cancer in order to determine possible tumour cells outside the prostate. Thanks to God, the tumour was localised only in one lobe of the prostate and no cells had been spread outside it.
As I learned about radiosurgery treatment possibilities, their benefits and possible complications, I agreed to be treated with that method.Prior to the treatment I read feedback from patients who were treated in Sigulda as well as experience of patients who were treated abroad.
There were several factors to the advantage of my choice: high-precision technology that delivers radiation exactly to a tumour thus saving the surrounding tissues as much as possible, low complication risk, no direct surgical invasion, painless procedure after which one can go home, short five days’ course of treatment that is adjusted to patient’s routine as well as deep understanding by the radiation oncologist and convincing perspective on my situation andsolutions.
I started treatment in March 2017. Sigulda Hospital is very up-to-date and patient-friendly establishment. In my case I headed for the procedure for five successive days with my car. Each session lasted for approximately one hour and during it I was lying peacefully, thinking over my life and felt no pain. After the session I went home by myself. Even though I had taken a vacation due to the treatment course, I think it would not be problematic to keep working during the treatment.
On a week following the treatment I had slight complaints about which I was already warned. Initially due to oedema I had difficult and more frequent urination, and more frequent elimination due to irritation, because the prostate is located very close to colon. As I observed the recommendations given by the specialists the side effects diminished within few weeks. Three months after the radiosurgery treatment course PSA indexes were back to norm—3.01 ng/ml and two more months later PSA stood at 1.47 ng/ml. At present moment I feel good. Potency is retained, there are no routine complaints about urination, perhaps only more frequent elimination is an issue but I call it nonsense. In dynamics I continue controlling PSA and observe situation on an out-patient’s basis at the urologist. I continue communication also with the Radiosurgery Centre’s specialists regarding the efficiency of my therapy.
I am grateful to Sigulda Hospital Radiosurgery Centre collective and especially Dr. Maris Mezeckis for being responsive,comprehensive and professional.”
Doctor’s commentary
In case of Gatis, we primarily applied CyberKnife M6 – a five-fraction radiosurgery procedure during which a maximum radiation dose is targeted at the lesion, yet the very prostate was radiated with conventional radiotherapy doses. In order to be able to apply this method, at first we made PET/CT examination with Ga68-PSMA, which made it possible to rule out local and distant metastases as well as to specify the location of the tumour in the prostate and its size.
Main advantages from the applied methods:
- Destruction of local tumour focus without surgical intervention;
- Possibility to maximally reduce side effects of other radical therapy;
- Decreased impact of therapy on potency and sexual function.
Peter from Great Britain (70), Prostate cancer, ogliometastases in lymph nodes, bones, ribs
Letter from the patient’s wife to Dr. Maris Mezeckis:
“Dear Maris,
We are more than happy with the treatment we have received from you. Your diligence, speed of response to medical questions and clear communication is the reason we chose to come to Latvia in the first place, rather than Eastern Europe, when we could not afford treatment in the UK. You have been excellent in always responding quickly and efficiently to any situation and we realised just how dedicated you are to your job, when we came for treatment in February. You should be very proud of the work you do and you are a credit to the Sigulda CyberKnife centre and therefore no apology was required. Your kindly manner and our trust in you was the reason we returned for further treatment, and your medical team are also excellent.
Kind regards
Peter and Marry”
Doctor’s commentary
Patient had a recurrence of disease after the radical prostatectomy and PET-CT showed tumour seeding in pelvic lymph nodes and bones. However the number of foci was not that big, therefore the hormonal therapy was supplemented with radiosurgery, giving a break to the hormonal therapy and implementing so-called intermittent hormonal therapy. This approach can reduce side effects of hormonal therapy and, possibly, delay formation of resistance to it. Besides, so-called abscopal effect can be observed regarding many tumours, including prostate cancer; it means that when destroying one lesion with radiation, lesions elsewhere in the body and tumour cells circulating in the body are oppressed by the immune system. It is because when tumour cells divide in the body their protein is released into bloodstream and this allows the immune system resisting other tumour cells.
Accessible
Affordable treatment is just a short flight away
An accessible treatment of a high standard should be available to all. Sigulda is about 45 minutes by car from Riga Airport, which has direct flights from many European cities. Prices are published in advance, and NHS or EU cross-border reimbursement may be possible.


Recognized
A Trusted Cancer Clinic in Northern Europe
Radiosurgery Centre Sigulda is certified by the International Stereotactic Radiosurgery Society (ISRS). The centre has treated patients with CyberKnife since 2015 and has performed more than 6,000 procedures.
Quality Over Quantity
Advantages of cancer treatment with CyberKnife
Download the Comprehensive
Prostate Cancer Guide
The guide is intended to help patients and their families better understand prostate cancer and the treatment options available. It is not a substitute for medical advice from a doctor, but it can be a helpful resource for making informed decisions about treatment.
Download the guide today and take the first step towards understanding prostate cancer.
© 2026 SRC Sigulda.